Alpha Tau to Participate in Ladenburg's Oncology Innovators & Investors Symposium
Alpha Tau to Participate in Ladenburg's Oncology Innovators & Investors Symposium
Founded in 2016, Alpha Tau is an Israeli oncology therapeutics company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. The technology was initially developed by Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv University.JERUSALEM, Dec. 06, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT, today announced that CFO Raphi Levy will present at the Ladenburg Oncology Innovators & Investors Symposium.
耶路撒冷，2024年12月6日（環球新聞）—— 阿爾法濤醫療有限公司（"阿爾法濤"，或稱"公司"）（納斯達克：DRTS，DRTSW），創新的α輻射癌症療法Alpha DaRt的開發者，今天宣佈首席財務官Raphi Levy將出席Ladenburg腫瘤創新者與投資者研討會。
| Event: | Ladenburg Oncology Innovators & Investors Symposium |
| Format: | Presentation and 1-on-1 Meetings |
| Date: | December 12, 2024 |
| Time: | 11:00AM – 11:25AM EST |
| Location: | Virtual |
| Event: | Ladenburg腫瘤創新者與投資者研討會 |
| 格式： | 演講和一對一會議 |
| 日期： | 2024年12月12日 |
| 時間： | 東部時間 11:00 - 11:25 |
| 地點： | 線上舉行 |
Please reach out to your Ladenburg representative to schedule 1-on-1 meetings with Mr. Levy.
請聯繫您的Ladenburg代表安排與Levy先生的1對1會議。
About Alpha Tau Medical Ltd.
關於Alpha Tau Medical Ltd.
Founded in 2016, Alpha Tau is an Israeli oncology therapeutics company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. The technology was initially developed by Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv University.
成立於2016年，Alpha Tau是一家以色列腫瘤治療公司，專注於Alpha DaRt固體腫瘤治療的研究、開發和潛在商業化。該技術最初由特拉維夫大學的Itzhak Kelson教授和Yona Keisari教授開發。
About Alpha DaRT
關於Alpha DaRT
Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is designed to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral delivery of radium-224 impregnated sources. When the radium decays, its short-lived daughters are released from the sources and disperse while emitting high-energy alpha particles with the goal of destroying the tumor. Since the alpha-emitting atoms diffuse only a short distance, Alpha DaRT aims to mainly affect the tumor, and to spare the healthy tissue around it.
Alpha DaRt（擴散性α放射性治療）旨在通過腫瘤內部注射鐳-224滲入源，實現對固體腫瘤的高效和成形α輻射。當鐳衰變時，其短壽命子核從源中釋放並散射，同時發射高能α粒子，旨在摧毀腫瘤。由於α放射性原子僅擴散一小段距離，Alpha DaRt旨在主要影響腫瘤，並儘量避免傷害周圍健康組織。
Investor Relations Contact: IR@alphatau.com
投資者關係聯繫方式：IR@alphatau.com
譯文內容由第三人軟體翻譯。
